A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML).
Silvia ParkDaehun KwagTong Yoon KimJong Hyuk LeeJoon Yeop LeeGi June MinSung Soo ParkSeung-Ah YahngYoung-Woo JeonSeung-Hwan ShinSung-Eun LeeByung Sik ChoKi-Seong EomYoo-Jin KimSung-Eun LeeChang-Ki MinSeok-Goo ChoJong Wook LeeHee-Je KimPublished in: Therapeutic advances in hematology (2022)
VEN combination provides a comparable anti-leukemic response and survival to salvage IC, and provide a bridge to SCT with better disease control in medically-fit patients with R/R AML.